Clinical Perspectives with Long‐Term Pulsed Inhaled Nitric Oxide for the Treatment of Pulmonary Arterial Hypertension
Open Access
- 1 April 2012
- journal article
- Published by Wiley in Pulmonary Circulation
- Vol. 2 (2) , 139-147
Abstract
Pulmonary arterial hypertension (PAH) is a chronic, progressive disease of the pulmonary vasculature with a high morbidity and mortality. Its pathobiology involves at least three interacting pathways – prostacyclin (PGI2), endothelin, and nitric oxide (NO). Current treatments target these three pathways utilizing PGI2 and its analogs, endothelin receptor antagonists, and phosphodiesterase type‐5 (PDE‐5) inhibitors. Inhaled nitric oxide (iNO) is approved for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term/near‐term neonates. As a selective pulmonary vasodilator, iNO can acutely decrease pulmonary artery pressure and pulmonary vascular resistance without affecting cardiac index or systemic vascular resistance. In addition to delivery via the endotracheal tube, iNO can also be administered as continuous inhalation via a facemask or a pulsed nasal delivery. Consistent with a deficiency in endogenously produced NO, long‐term pulsed iNO dosing appears to favorably affect hemodynamics in PAH patients, observations that appear to correlate with benefit in uncontrolled settings. Clinical studies and case reports involving patients receiving long‐term continuous pulsed iNO have shown minimal risk in terms of adverse events, changes in methemoglobin levels, and detectable exhaled or ambient NO or NO2. Advances in gas delivery technology and strategies to optimize iNO dosing may enable broad‐scale application to long‐term treatment of chronic diseases such as PAH.Keywords
Funding Information
- Ikaria
This publication has 69 references indexed in Scilit:
- Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertensionEuropean Respiratory Journal, 2011
- Therapeutic approaches using nitric oxide in infants and childrenFree Radical Biology and Medicine, 2011
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial HypertensionJACC, 2009
- A meta-analysis of randomized controlled trials in pulmonary arterial hypertensionEuropean Heart Journal, 2008
- Use of Sildenafil to Facilitate Weaning From Inhaled Nitric Oxide in Children With Pulmonary Hypertension Following Surgery for Congenital Heart DiseaseJournal of Intensive Care Medicine, 2008
- Inhaled NO as a therapeutic agentCardiovascular Research, 2007
- Pharmacotherapy of Acute Lung Injury and the Acute Respiratory Distress SyndromeJournal of Intensive Care Medicine, 2006
- Hemodynamic effects of inhaled nitric oxide in right ventricular myocardial infarction and cardiogenic shockJACC, 2004
- Inhaled Nitric Oxide for the Adult Respiratory Distress SyndromeNew England Journal of Medicine, 1993